ライフサイエンスコーパス: pain

1 ful cramps, nociceptive pain, or neuropathic pain).

2 gG seropositive (7% had solely neuropathy or pain).

3 d for ultrasound and MRI because of shoulder pain.

4 t of the clinical evaluation of stable chest pain.

5 hemia, or new uncontrollable hypertension or pain.

6 e system is a basic mechanism of neuropathic pain.

7 lation was not observed in those with ocular pain.

8 current, and unpredictable episodes of acute pain.

9 and nonpharmacologic treatments for low back pain.

10 etuate a noxious microenvironment leading to pain.

11 rsensitivity, a major symptom of neuropathic pain.

12 uits are altered in individuals with chronic pain.

13 gesic therapies for the treatment of chronic pain.

14 tress-induced inflammatory exacerbations and pain.

15 been implicated as a key mediator of chronic pain.

16 nal changes and the development of prolonged pain.

17 ons, including osteoarthritis and lower back pain.

18 lete Freund's adjuvant model of inflammatory pain.

19 oke, neuronal inflammation, and pathological pain.

20 g as a new treatment modality in neuropathic pain.

21 ed erythema, wheezing, nausea, and abdominal pain.

22 the development and maintenance of prolonged pain.

23 iotics have the potential to modify visceral pain.

24 t evidence exists for other types of chronic pain.

25 and memory impairments comorbid with chronic pain.

26 lators of tumor- and nerve injury-associated pain.

27 most widely used drugs for the treatment of pain.

28 idermal water loss, and participant-assessed pain.

29 adjuvant, a model of peripheral inflammatory pain.

30 ive and the sensory component of neuropathic pain.

31 d formalin pain responses and decreased heat pain.

32 ntribute to nerve injury-induced neuropathic pain.

33 ulting delay in the onset of PDAC-associated pain.

34 to moderate, primarily short-term effects on pain.

35 nt algorithms designed to target neuropathic pain.

36 rsensitivity, a major symptom of neuropathic pain.

37 in 6 patients; 8 patients experienced severe pain.

38 when they viewed pictures of others' hand in pain.

39 2F) that is associated with insensitivity to pain.

40 adder sensory afferents temporarily relieves pain.

41 tribution resulting in disabling neuropathic pain.

42 sion (124 [17%] of 713 responses), abdominal pain (178 [22%]), and ocular disorders (142 [18%]).

43 mptoms (324 [40%] patients), musculoskeletal pain (303 [38%]), headache (278 [35%]), depression (124

44 shortness of breath; 47% wheezing; 46% chest pain; 42% abnormal peak flow), 334 (84%) provided cough

45 us placebo within the first 14 days were arm pain (57.4% [27 of 47] vs 7.4% [seven of 94]) and local

46 ears or older with chronic and frequent knee pain, a Western Ontario McMaster Universities Osteoarthr

47 -recognized problem, with moderate to severe pain affecting 15% to 20% of women at 1 year from surger

48 nt and Emergency Department with right ankle pain after an inversion injury and underwent plain radio

49 Purpose Persistent pain after breast cancer surgery is a well-recognized pr

50 tients at high risk of developing persistent pain after breast cancer surgery.

51 t in nonpharmacological treatments to reduce pain after total knee arthroplasty.

52 cally-significant predictor of incident back pain among female subjects (odds ratio [OR]: 1.75, 95% c

53 tral mechanisms underlying exercised-induced pain and analgesia.

54 It is often sensory-predominant with pain and can lead to long-term morbidity in survivors.

55 Osteoarthritis (OA) is a common cause of pain and disability and is often associated with the deg

56 s protect organisms from danger by eliciting pain and driving avoidance.

57 component of many medications used to treat pain and fever worldwide.

58 resented more frequently with atypical chest pain and had a lower pretest probability of coronary art

59 hould assess whether therapies to ameliorate pain and inflammation in RA restores autonomic balance a

60 way for small-molecule drug design targeting pain and inflammation.

61 ns could produce approaches to treat chronic pain and inflammatory diseases.

62 of PPAR-alpha and an important regulator of pain and innate immunity.

63 n of Chest Pain), patients with stable chest pain and intermediate pretest probability for obstructiv

64 that receive direct synaptic input from both pain and itch primary sensory neurons.

65 er, the role of PD-L1 and PD-1 in regulating pain and neuronal function is unclear.

66 led trials in adults with chronic non-cancer pain and opioid-induced constipation.

67 Pain and pain-related disability were assessed with the

68 enefit for treating chronic gastrointestinal pain and painful FGIDs and serotonin noradrenergic reupt

69 ical disorder, associated with severe pelvic pain and reduced fertility; however, its molecular mecha

70 gical disorder characterized by debilitating pain and the establishment of innervated endometriosis l

71 rent input in the maintenance of neuropathic pain and the potential for targeted chemogenetic silenci

72 me measures included the time until onset of pain and the time until patients required rescue medicat

73 robust motosensory improvement, neuropathic pain and tissue damage mitigation, and myelin preservati

74 CRS cases who reported smell loss and facial pain and/or pressure and had the weakest associations wi

75 SK relapses had lower QoL related to "ocular pain" and "acknowledgement." Even during a quiescent pha

76 0%) had a decrease or complete resolution of pain, and 12 patients (60%) no longer required opioid th

77 e to the generation of epilepsy, neuropathic pain, and autism spectrum disorders; thus, it is importa

78 oids are increasingly used to manage chronic pain, and chronic opioid users are challenging to care f

79 inellosis, characterized by fever, abdominal pain, and diarrhea, along with eosinophilia ranging from

80 us system, such as chronic nausea, vomiting, pain, and hypertension.

81 y can cause side-effects including bleeding, pain, and infection.

82 rly serve individuals suffering from chronic pain, and new therapeutic agents that are more effective

83 tonic pain, in capsaicin-induced neurogenic pain, and notably in oxaliplatin-induced neuropathic pai

84 mmation, clearance of microbes, reduction of pain, and promotion of tissue regeneration via novel mec

85 l index, transcutaneous oxygen tension, rest pain, and walking capacity after cell therapy.

86 Several systemic medications for low back pain are associated with small to moderate, primarily sh

87 he exact molecular mechanisms of HIV-related pain are still elusive.

88 ated conditions, but its effects on low back pain are uncertain.

89 st 1 skeletal-related event by disease type, pain as assessed by the Brief Pain Inventory (range, 0-1

90 Regional gray matter alterations in chronic pain, as detected with voxel-based morphometry of anatom

91 ing nurses' use of standardized measures for pain assessment.

92 In contrast to their role in inflammatory pain aversion, EP3 receptors on serotonergic cells were

93 0 are potential drug targets for neuropathic pain because they form a channel complex with the K(+) c

94 can produce a complete cessation of chronic pain behaviors in mice.

95 tical role in CeA plasticity and neuropathic pain behaviors in the rat spinal nerve ligation (SNL) mo

96 commonly used treatment for chronic low back pain, but high-quality evidence for its effectiveness is

97 Opiates are essential for treating pain, but termination of opiate therapy can cause a debi

98 RVM GABAergic neurons facilitate mechanical pain by inhibiting dorsal horn enkephalinergic/GABAergic

99 It is less clear, however, if chronic pain can also induce a generalized site-nonspecific enha

100 ived clinical diagnoses of chronic noncancer pain conditions in the last year of life.

101 thma, anxiety, depression, and other chronic pain conditions, and these comorbidities add to the amou

102 ularly those who were diagnosed with chronic pain conditions, commonly received services related to d

103 , nor whether ADS is altered in inflammatory pain conditions.

104 erventions in a number of unilateral chronic pain conditions.

105 or second eye surgery affect intra-operative pain control or are correlated with type of anesthesia m

106 stopped or used no opioids owing to adequate pain control, and 16% to 29% of patients reported opioid

107 Mu opioid receptors (MORs) are central to pain control, drug reward, and addictive behaviors, but

108 The physiological origin of this pain (critical to its treatment) remains unknown, althou

109 eaked on days 10-11 after treatment, without pain, crusting, or ulceration.

110 The site of pain depends on the pain type or underlying mechanism (e

111 As compared with decedents without chronic pain diagnoses, those with these diagnoses were signific

112 nts, mostly mild self-limited joint and back pain, did not differ between the yoga and PT groups.

113 OHIP-14 physical pain dimension had positive correlation with CDH (P <0.0

114 ary endpoint was a >/=50% improvement on the Pain Disability Index in 50% of patients with active DBS

115 self-care, 47% for usual activities, 50% for pain/discomfort, and 41% for anxiety/depression.

116 ezing cold injury is a disabling neuropathic pain disorder due to a sensory neuropathy.

117 ical studies show that patients with chronic pain display altered pain-modulation efficacy, it remain

118 y (range, 0-10; higher scores indicate worse pain), Eastern Cooperative Oncology Group performance st

119 practical, effective means to reduce surgeon pain, enhance performance, and increase mental focus wit

120 ears with moderate to severe acute extremity pain enrolled from July 2015 to August 2016.

121 s bloating, overfilled intestines, abdominal pain, excessive feces, steatorrhea, and malnutrition.

122 etworks that interact to produce the overall pain experience.

123 Pain experienced by patients may reflect surgical compli

124 ting room staff from 4 medical centers rated pain/fatigue, physical, and mental performance using val

125 ally available drugs to treat tactile-driven pain following neuropathy.

126 ce might not be horizontally symmetric as in pain-free individuals, but instead larger around the aff

127 was defined as a 50% or greater reduction in pain frequency and intensity scores.

128 Neuropathic pain frequently leads to decisions about using long-term

129 Randomized trials that reported pain, function, or harms of systemic medications versus

130 ed disability were assessed with the chronic pain grade questionnaire.

131 Coding of itch versus pain has been heatedly debated for decades.

132 Animal models of exercise-induced pain have been developed and point to central mechanisms

133 ascular and neurological aetiologies of this pain have been suggested but remain unproven.

134 Although a large number of PAINS have been classified, often on the basis of indivi

135 rved in a model of the transition to chronic pain, hyperalgesic priming.

136 sive motion and preoperative exercise had no pain improvement and reduction in opioid consumption: fo

137 istory of depression predicted incident back pain in a population of military registered nurses when

138 SUMMARY OF IPLA reduces pain in adult elective surgery.

139 had an ultrasound examination because of the pain in left lumbar region.

140 V 1.7 is required for acute and inflammatory pain in mice and humans but its significance for viscera

141 d for sensing acute and inflammatory somatic pain in mice and humans but its significance in pain ori

142 d notably in oxaliplatin-induced neuropathic pain in mice.

143 eful to rule out other causes of acute chest pain in patients admitted to the emergency department.

144 ity of sensory neurons and thereby to reduce pain in patients treated with this chemotherapeutic agen

145 y drugs (NSAIDs), and corticosteroids reduce pain in patients with acute gout.

146 ty in formalin-, carrageenan- or FCA-induced pain in rodents when administered systemically.

147 Current treatment of moderate to severe pain in SCD is mostly reliant upon opioids; however, lon

148 c and/or preventive strategies to ameliorate pain in SCD.

149 association with the development of chronic pain in several clinical cohorts of temporomandibular di

150 ests that cannabis may alleviate neuropathic pain in some patients, but insufficient evidence exists

151 We also review the management of chronic pain in special populations of PLWH, including persons w

152 rt a large-scale analysis of the behavior of PAINS in biological screening assays.

153 ing pain responses in formalin-induced tonic pain, in capsaicin-induced neurogenic pain, and notably

154 plified in the assessment of acute abdominal pain, in which a physician's palpation determines if a p

155 new target for the treatment of neuropathic pain, including chemotherapy (paclitaxel)-induced neurop

156 glia, spinal slices, and in a mouse model of pain induced by NaV1.7 activation, Pn3a alone displayed

157 hyperexcitability associated with persistent pain induced by spinal cord injury (SCI).

158 may be associated with short-term effects on pain intensity and physical functioning.

159 At week 52, the mean unadjusted leg-pain intensity score was 3.4 in the pregabalin group and

160 These include pain interference (52.4), fatigue (52.2), and physical f

161 y), fatigue (55.8 v 50.2, respectively), and pain interference (55.2 v 50.9, respectively).

162 went autologous reconstruction had increased pain interference (difference, 2.0; P = .006).

163 disease type, pain as assessed by the Brief Pain Inventory (range, 0-10; higher scores indicate wors

164 discovery, prosthetic design and neuropathic pain investigations.

165 Pain is a frequently reported symptom by patients approa

166 Pain is a largely neglected symptom in patients with amy

167 Pain is correlated with a deterioration in patients' qua

168 Chronic pain is increasingly recognized as an important comorbid

169 sician's palpation determines if a patient's pain is life-threatening requiring emergency interventio

170 Observations: Low back pain is rarely seen in youth before they reach school ag

171 and humans but its significance for visceral pain is unknown.

172 Chronic pain itself cannot be ruled out as a source of worsened

173 ofen and dexamethasone significantly reduced pain (Kruskal-Wallis; P <0.05) up to 3 days after surger

174 bition had a similar relieving effect on the pain-like behavior.

175 ) is a fibro-inflammatory disease leading to pain, maldigestion, and pancreatic insufficiency.

176 t a need to improve access to evidence-based pain management and to decrease excessive prescribing th

177 Promising new approaches to pain management capitalize on the brain's own mechanisms

178 aff development program, designed to improve pain management in hospitals.

179 Pain management of patients with chronic pancreatitis (C

180 ritical revisiting and modification of prior pain management practices (e.g., guidelines from the Cen

181 certainty evidence that acupuncture improved pain (mean difference, -1.14; 95% CI, -1.90 to -0.38 on

182 p reported significantly more improvement in pain (mean difference, 1.6 units [95% CI, 0.9 to 2.3 uni

183 Secondary outcomes included pain medication use, global improvement, satisfaction wi

184 observed in response to the HFD, absent any pain model.

185 europathic nociception in either neuropathic pain model.

186 neuropathic and in acute/tonic inflammatory pain models.

187 iad preclinical inflammatory and neuropathic pain models.

188 as increased activation of NMDA receptors in pain-modulating areas.

189 placebo hypoalgesia, treatment context) with pain modulation through stimulus intensity cues (stimulu

190 We compared pain modulation through treatment cues (placebo hypoalge

191 ficacy, it remains unknown whether brainstem pain-modulation circuits are altered in individuals with

192 t patients with chronic pain display altered pain-modulation efficacy, it remains unknown whether bra

193 ctivity between regions within the brainstem pain-modulation network.

194 a period of rapid brain development, before pain modulatory systems reach maturity, will predict pro

195 The most frequent local effects were pain (n=40 [60%]) or tenderness (n=32 [47%]) at the inje

196 icating that the structural context in which PAINS occur modulates their effects.

197 Results Moderate to severe persistent pain occurred in 13.5%, 13.9%, and 20.3% of the patients

198 The patient reported pain of 8-10 in VAS (Visual Analogue Scale) and had an O

199 h previously observed alterations in chronic pain offer a novel interpretation of aberrant pain proce

200 immune disorder (two [13%]), lower abdominal pain (one [7%]), fatigue (one [7%]), and influenza-like

201 cal and thoracic lesions that persisted from pain onset to 'out of relapse' follow-up (current MRI) h

202 ehaviors and for aversion induced by thermal pain or a kappa opioid receptor agonist.

203 commended in patients with chronic abdominal pain or diarrhea, in whom there was no evidence of abnor

204 disagreement for symptoms of blurry vision, pain or discomfort, and redness.

205 ated, because the helmet-type mask caused no pain or discomfort, as compared to the face mask.

206 iatic nerve transection model of neuropathic pain or in the Complete Freund's adjuvant model of infla

207 Of patients presenting with pain or peripheral nervous system (PNS) manifestations,

208 ation at the time; for example, there was no pain or rapid growth.

209 g mechanism (eg, painful cramps, nociceptive pain, or neuropathic pain).

210 n in mice and humans but its significance in pain originating from the viscera is unknown.

211 ency department for evaluation of persistent pain over the volar portion of his right fifth finger af

212 s of ASIC3, which has a specific role in the pain pathway.

213 ramework of cold allodynia-activated central pain pathways.

214 debilitating symptom for millions of chronic pain patients.

215 center Imaging Study for Evaluation of Chest Pain), patients with stable chest pain and intermediate

216 and (b) evaluate the quality of life (QOL), pain perception, and efficacy in terms of time to local

217 n the brain's own mechanisms for controlling pain perception.

218 t afferent nociceptive signals into a stable pain perception.

219 nal mPFC deactivation that is causal for the pain phenotype and represents a cellular mechanism for t

220 ain offer a novel interpretation of aberrant pain processing as disturbed weighting of predictions an

221 However, the impact of ADS on spinal pain processing has not been explored, nor whether ADS i

222 This novel functional dissociation of pain processing within the insula together with previous

223 entations, such as value, can modulate early pain processing.

224 suppressed chemotherapy-induced neuropathic pain produced by paclitaxel without producing tolerance.

225 center Imaging Study for Evaluation of Chest Pain (PROMISE) trial, readers at 193 North American site

226 icant or clinically important differences in pain reduction at 2 hours among single-dose treatment wi

227 more than 25% of patients with stable chest pain referred for noninvasive testing will have normal c

228 The most common adverse event was pain related to surgical incision or positioning that re

229 -HT2CR in the BLA contributes to neuropathic-pain-related amygdala plasticity by driving synaptic exc

230 reduction (MBSR) is frequently used to treat pain-related conditions, but its effects on low back pai

231 Pain and pain-related disability were assessed with the chronic p

232 ro-Stim has sustained efficacy for abdominal pain-related functional gastrointestinal disorders in ad

233 ss than half of patients report satisfactory pain relief from current treatments.

234 targeting central sites may be required for pain relief once BTP has been initiated.

235 For effective interventions, pain relief was small to moderate and generally short-te

236 s simple, does not require surgery, provides pain relief, and significantly improves disc quality.

237 e them attractive candidates for therapeutic pain relief.

238 bility of analgesics, including opioids, for pain relief.

239 ations of RVM neurons facilitate or diminish pain remain elusive.

240 cacious in treatment of chronic nonmalignant pain remains controversial.

241 The Pain Resource Nurse program is a widely disseminated, ev

242 The Pain Resource Nurse program was successful in improving

243 jective was to test the effectiveness of the Pain Resource Nurse program.

244 male DRD5KO mice also show reduced formalin pain responses and decreased heat pain.

245 33 demonstrated effectiveness by decreasing pain responses in formalin-induced tonic pain, in capsai

246 hly significant (p<0.01) opposing effects on pain scores (std.

247 the area under the curve (AUC) of cumulative pain scores from end of surgery to 6 h postsurgery.

248 17-HDHA was associated with lower pain scores in OA patients (beta -0.41; 95% CI-0.69, -0.

249 TSMB improved surgeon postprocedure pain scores in the neck, lower back, shoulders, upper ba

250 e-to-low trajectories based on postoperative pain scores.

251 findings also support the use of neuropathic pain screening tools in these patients and treatment alg

252 two randomized trials of BMAs in control of pain secondary to bone metastases.

253 ociceptive responses are used as measures of pain sensation in newborn humans, as they are in animals

254 ning, fear behaviors, neurodegeneration, and pain sensation.

255 Moreover, this mouse exhibits increased pain sensitivity, a phenotype that is consistent with in

256 g, is essential in maintaining physiological pain sensitivity, and is diminished in pathological pain

257 otential influence of collateral branches on pain sensitivity.

258 Pain serves vital protective functions.

259 aining 16 patients evaluable for safety were pain (seven [44%] of 16), hypokalaemia (six [38%]), neut

260 ty of evidence), improvement was reported in pain severity (8 of 8 fair-quality studies), function (5

261 ial functioning, psychological distress, and pain severity at 4 and 24 weeks.

262 re, and treatment algorithms for neuropathic pain should now be used in the management of these patie

263 that individuals with orofacial neuropathic pain show altered functional connectivity between region

264 rat model of oxaliplatin-induced neuropathic pain, showed the better antihypersensitive profile being

265 e also plays an important role in mechanical pain signaling by primary afferent somatosensory neurons

266 Peripheral pain signaling reflects a balance of pronociceptive and

267 rect microbial dysbiosis may impact visceral pain.SIGNIFICANCE STATEMENT Commercially available probi

268 hemotherapy (paclitaxel)-induced neuropathic pain.SIGNIFICANCE STATEMENT This work demonstrates that

269 target against inflammatory and neuropathic pain.SIGNIFICANCE STATEMENT We demonstrate that hyaluron

270 EBPbeta in the HIV gp120-induced neuropathic pain state.

271 nsitivity, and is diminished in pathological pain states.

272 The same PAINS substructure was often found in consistently inact

273 lso were associated with nonspinal causes of pain, such as facet joint degeneration, pars defect, or

274 hy in the left upper and lower limbs without pain, swelling, or skin lesions was noted at physical ex

275 atients from a large family with early-onset pain symptoms were evaluated by clinical examination and

276 arm's reach, patients with complex regional pain syndrome exhibited a bias away from the affected si

277 al testing of patients with complex regional pain syndrome has found evidence for spatial biases when

278 wn is whether patients with complex regional pain syndrome only have biased attention for bodily-spec

279 Some patients with complex regional pain syndrome report that movements of the affected limb

280 thalamic bursts are an adaptive response to pain that de-synchronizes cortical theta and decreases s

281 The patient reported mild pain that was adequately controlled with over-the-counte

282 ts presenting to the ED with acute extremity pain, there were no statistically significant or clinica

283 interneurons gate sensory inputs and control pain through temporally coordinated enkephalin- and GABA

284 Symptoms may range from mild abdominal pain to life-threatening obstruction and strangulation.

285 Patients in the high pain trajectories had the highest rates of postdischarge

286 nct postoperative inpatient patient-reported pain trajectories were identified: (1) persistently low,

287 , and gastro-intestinal function, as well as pain transmission.

288 The site of pain depends on the pain type or underlying mechanism (eg, painful cramps, n

289 In extremely preterm neonates early pain was associated with decreased thalamic NAA/Cho and

290 More pain was associated with reduced GMVs and NAA/Cr, over a

291 Pain was estimated using the 36-Item Short Form Survey.

292 In RA patients, reported pain was positively correlated with MSNA and negatively

293 Relief from physical pain was the most commonly reported motivation for misus

294 in the survival data.Mean symptom scores for pain were significantly higher in the TTIL group than in

295 ncy, female mice show no evidence of chronic pain whatsoever.

296 us, causes febrile disease, muscle and joint pain, which can become chronic in some individuals.

297 les that manifests as prolonged excruciating pain, which has proven difficult to treat.

298 -year-old man developed right lower quadrant pain while traveling.

299 identification of those patients with chest pain who require admission and urgent management and tho

300 dred seventeen patients with acute abdominal pain who underwent abdominal CT were enrolled in this re